1. Mitophagy as a Protective Mechanism against Myocardial Stress
   Jihoon Nah et al, 2017 CrossRef
2. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities
   Jyotika Rajawat et al, 2017, Med. Res. Rev. CrossRef
3. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells
   Biao Wan et al, 2018, Endocr Relat Cancer CrossRef
4. Repairing Mitochondrial Dysfunction in Disease
   Vincenzo Sorrentino et al, 2018, Annu. Rev. Pharmacol. Toxicol. CrossRef
5. Applications of RNA Indexes for Precision Oncology in Breast Cancer
   Liming Ma et al, 2018, Genomics, Proteomics & Bioinformatics CrossRef
6. Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma
   Hangzhan Ma et al, 2018, Oncology CrossRef
7. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines
   Bahram Sharif-Askari et al, 2018, Breast Cancer Res Treat CrossRef
8. Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness
   Michael D. Tarpey et al, 2018, J Physiol CrossRef
9. The pharmacological regulation of cellular mitophagy
   Nikolaos D Georgakopoulos et al, 2017, Nat Chem Biol CrossRef
10. Poly (ADP‐ribose) polymerase inhibition protects against myocardial ischaemia/reperfusion injury via suppressing mitophagy
    Shengchuan Cao et al, 2019, J Cell Mol Med CrossRef
11. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors
    Daniela Passeri et al, 2016, ChemMedChem CrossRef
12. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.
    T Jubin et al, 2016, Cell Prolif CrossRef
13. Triple negative breast cancer: Deciphering the biology and heterogeneity
    G.I. Uscanga-Perales et al, 2016, Medicina Universitaria CrossRef
14. Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma
    Yunxiang Ji et al, 2019, Appl Microbiol Biotechnol CrossRef
15. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Janice M Santiago-O'Farrill et al, 2020, Cancer CrossRef
16. Vías moleculares de regulación de la autofagia por BRCA1: Implicaciones en cáncer
    Juan M. Esteve et al, 2019, Revista Española de Patología CrossRef
17. PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis
    Csaba Hegedűs et al, 2019, Cancers CrossRef
18. Silencing of PARP2 Blocks Autophagic Degradation (Running Title: PARP2 Is an Inhibitor of Autophagy)
    Laura Jankó et al, 2020, Cells CrossRef
19. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition
    Olga Villamar Cruz et al, 2016, Oncotarget CrossRef
20. PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer
    Danna Yeerken et al, 2020, PLoS ONE CrossRef
21. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery
    Oliver Trusler et al, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
22. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo
    Franziska Briest et al, 2021, Neoplasia CrossRef
23. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells
    Xiaochen Wu et al, 2020, Food and Chemical Toxicology CrossRef
24. BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
    Susan Morand et al, 2020 CrossRef
25. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability
    A. Selen Gurkan-Alp et al, 2020, ACAMC CrossRef
26. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
    Francesco Schettini et al, 2021, European Journal of Cancer CrossRef
27. Identifying the Cellular Target of a Cordyheptapeptide A and Synthetic Derivatives
    Victoria G. Klein et al, 2021, ACS Chem. Biol. CrossRef
28. The Present and Future of the Treatment of Hereditary Breast Cancer
    Jose Russo, 2021 CrossRef
29. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA
    Cheng Wang et al, 2021, J. Med. Chem. CrossRef
30. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer
    Elif Asik et al, 2019, Nanomedicine CrossRef
31. Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
    Arafat Siddiqui et al, 2021, Front. Oncol. CrossRef
32. Improved anticancer activity of betulinic acid on breast cancer through a grafted copolymer-based micelles system
    Xueju Qi et al, 2021, Drug Delivery CrossRef
33. DNA damage response and Breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition
    Mohammad Mirza-Aghazadeh-Attari et al, 2020, DNA Repair CrossRef
34. Enhancing autophagy in Alzheimer's disease through drug repositioning
    Mehdi Eshraghi et al, 2022, Pharmacology & Therapeutics CrossRef
35. Pre-activation of autophagy impacts response to olaparib in prostate cancer cells
    Maxime Cahuzac et al, 2022, Commun Biol CrossRef
36. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
    Naomie Devico Marciano et al, 2022, Cancers CrossRef
37. Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer
    Nan Wang et al, 2022, JIR CrossRef
38. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity
    Clara García-Carro et al, 2022, Nephron CrossRef
39. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumor-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer
    Nageswara Rao Vysyaraju et al, 2022, Journal of Drug Targeting CrossRef
40. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
    Jiaqi Xiong et al, 2022, Seminars in Cancer Biology CrossRef
41. A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer
    Malene Blond Ipsen et al, 2022, Oncogene CrossRef
42. Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
    Lulu Li et al, 2021, CMC CrossRef
43. Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
    Maxime Cahuzac et al, 2022, Cancers CrossRef
44. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding
    Suzanne Bartholf DeWitt et al, 2022 CrossRef
45. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice
    Li-Mei Chen et al, 2022, J Biomed Sci CrossRef
46. Guangsangon E triggers mitochondria dysfunction and mitophagy in triple‐negative breast cancer and leads to non‐apoptotic cell death
    Yuhang Shen et al, 2022, Molecular Carcinogenesis CrossRef
47. Role of Medicinal plant‐derived Nutraceuticals as a potential target for the treatment of breast cancer
    Khalid Saad Alharbi et al, 2022, Journal of Food Biochemistry CrossRef
48. Recent advances in cancer therapy using PARP inhibitors
    Simran Deep Kaur et al, 2022, Med Oncol CrossRef
49. BRCA Biological Functions
    Divya Bhargavi Pulukuri et al, 2022 CrossRef
50. Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
    Danfeng Shi et al, 2022, Front. Pharmacol. CrossRef
51. Promotion of a synthetic degradation of activated STAT6 by PARP-1 inhibition: roles of poly(ADP-ribosyl)ation, calpains and autophagy
    Jeffrey Wang et al, 2022, J Transl Med CrossRef
52. An AI-guided screen identifies probucol as an enhancer of mitophagy through modulation of lipid droplets
    Natalia Moskal et al, 2023, PLoS Biol CrossRef
53. Mitophagy Enhancer Identified in Repurposing Screen for Parkinson's Disease Therapeutics
    Natalia Moskal et al, 2021, SSRN Journal CrossRef
54. Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response
    Mehrdad Hashemi et al, 2023, Biomedicine & Pharmacotherapy CrossRef
55. DNA repair pathways in breast cancer: from mechanisms to clinical applications
    Muhammad Tufail, 2023, Breast Cancer Res Treat CrossRef
56. Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase
    Vanishree Rao et al, 2023, CNSNDDT CrossRef
57. РАК МОЛОЧНОЇ ЗАЛОЗИ, АСОЦІЙОВАНИЙ З МУТАЦІЄЮ 5382INSC У ГЕНІ BRCA1
    С. А. Лисенко et al, 2023, АПП CrossRef
58. Meteorin-like (METRNL) attenuates hypertensive induced cardiac hypertrophy by inhibiting autophagy via activating BRCA2
    Jun Li et al, 2024, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
59. Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena
    Raed Obaid Saleh et al, 2024, Cell Biochemistry & Function CrossRef
60. The Genetic Basis of Neuroendocrine Neoplasms
    Amanda R. Wasylishen et al, 2024 CrossRef
61. Macrophage migration inhibitory factor (MIF) suppresses mitophagy through disturbing the protein interaction of PINK1-Parkin in sepsis-associated acute kidney injury
    Tianlong Li et al, 2024, Cell Death Dis CrossRef
62. ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines
    Holda Awah Anagho et al, 2024, Cell Reports CrossRef
63. BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork
    Corrado Tinterri et al, 2024, Current Oncology CrossRef
64. Astragalus polysaccharides sensitize ovarian cancer stem cells to PARPi by inhibiting mitophagy via PINK1/Parkin signaling
    Qiaohua Peng et al, 2024, iScience CrossRef
65. Fourier-domain-compressed optical time-stretch quantitative phase imaging flow cytometry
    Rubing Li et al, 2024, Photon. Res. CrossRef
66. Complex Interplay between DNA Damage and Autophagy in Disease and Therapy
    Aman Singh et al, 2024, Biomolecules CrossRef
67. Management of human epidermal growth factor receptor 2–negative metastatic breast cancer
    Ashok Kumar Vaid et al, 2022 CrossRef
68. Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy
    Janice M. Santiago-O’Farrill et al, 2024 CrossRef
69. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
    Miki Kawanishi et al, 2022, Breast Cancer�(Auckl) CrossRef
70. Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
    Constanze Schneider et al, 2024 CrossRef
71. Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application
    Suyakarn Archasappawat et al, 2024, Biomolecules CrossRef
72. Mitophagy: insights into its signaling molecules, biological functions, and therapeutic potential in breast cancer
    Cong Chen et al, 2024, Cell Death Discov. CrossRef
73. Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation
    Quratul Ain et al, 2024, European Journal of Surgical Oncology CrossRef
74. Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency
    Juanjuan Liu et al, 2024, Front. Pharmacol. CrossRef
75. Nanotherapeutic strategy against glioblastoma using enzyme inhibitors
    Rekha Thiruvengadam et al, 2024, Biomedicine & Pharmacotherapy CrossRef